HR| Breast Cancer

FDA Greenlights First Targeted Therapy for PIK3CA Wild-Type HR+/HER2− Advanced Breast Cancer

OncoNexus July 16, 2026

The FDA has approved gedatolisib (Revtorpyk) plus fulvestrant, with or without palbociclib, as the first targeted therapy for PIK3CA wild-type HR+/HER2− advanced breast cancer. Learn about the VIKTORIA-1 data, efficacy outcomes, safety profile, and clinical…

Multiple Myeloma (MM), Blood Cancer

FDA Approves Subcutaneous Isatuximab Across Multiple Myeloma Treatment Settings

Colorectal Cancer, GI Cancer

Signatera MRD Status Predicts Survival Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

Non-Muscle Invasive (NMIBC), Urothelial Carcinoma

FDA Clears IND for UGN-501, UroGen’s Next-Generation Investigational Therapy for NMIBC

Colorectal Cancer

New Data Link Bowel Habit Changes With Early-Onset Colorectal Cancer Risk

View All

View All

FDA Greenlights First Targeted Therapy for PIK3CA Wild-Type HR+/HER2− Advanced Breast Cancer

July 16, 2026

The FDA has approved gedatolisib (Revtorpyk) plus fulvestrant, with or without palbociclib, as the first targeted therapy for PIK3CA wild-type…

FDA Approves First CDK4/6 Inhibitor-Based Maintenance Regimen for HR+/HER2+ Metastatic Breast Cancer

June 25, 2026

The FDA has approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment…

Trodelvy Expands Into the Frontline With Dual FDA Approval in Advanced TNBC

June 25, 2026

The FDA has approved sacituzumab govitecan-hziy (Trodelvy) as both monotherapy and in combination with pembrolizumab for first-line treatment of unresectable…

[sureforms id=’2716′]

View All

Multiple Myeloma (MM)

ASH 2025: Optimizing MM Care: Key Trials and Consensus Updates on Targeted, Immune-Based, and Risk-Adapted Approaches

Explore recent pivotal trials and consensus updates in multiple myeloma, including MajesTEC-3, COBRA, and the first IMS–IMWG high-risk definition. This…

Muscle Invasive (MIBC)

Atezolizumab Approved for Adjuvant Use in MRD Positive Muscle Invasive Bladder Cancer

Atezolizumab (Tecentriq) and Tecentriq Hybreza have been FDA approved as the first ctDNA-guided adjuvant immunotherapy options for patients with MIBC…

Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?

OncologyNexus Team August 13, 2025

SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but…

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer

OncologyNexus Team August 13, 2025

ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes…

Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort

OncologyNexus Team August 18, 2025

PTL is a rare extranodal malignancy accounting for <5% of thyroid cancer,…

Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance

August 5, 2025 No Comments

XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV…

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

August 6, 2025 No Comments

CR rates greater than 80% achieved with TAR-200 device -…

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

August 7, 2025 No Comments

Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast…

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

August 13, 2025 No Comments

T-DXd plus pertuzumab nearly doubled progression-free survival compared to standard…

Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results

Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients

OncologyNexus Team August 12, 2025

“Steroids were the biggest predictor of why certain immunotherapies may not be…

FDA Greenlights First Targeted Therapy for PIK3CA Wild-Type HR+/HER2− Advanced Breast Cancer

FDA Approves Subcutaneous Isatuximab Across Multiple Myeloma Treatment Settings

Signatera MRD Status Predicts Survival Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

FDA Clears IND for UGN-501, UroGen’s Next-Generation Investigational Therapy for NMIBC

New Data Link Bowel Habit Changes With Early-Onset Colorectal Cancer Risk

FDA Greenlights First Targeted Therapy for PIK3CA Wild-Type HR+/HER2− Advanced Breast Cancer

FDA Approves First CDK4/6 Inhibitor-Based Maintenance Regimen for HR+/HER2+ Metastatic Breast Cancer

Trodelvy Expands Into the Frontline With Dual FDA Approval in Advanced TNBC

ASH 2025: Optimizing MM Care: Key Trials and Consensus Updates on Targeted, Immune-Based, and Risk-Adapted Approaches

Atezolizumab Approved for Adjuvant Use in MRD Positive Muscle Invasive Bladder Cancer

Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer

Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort

Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results

BREAKWATER Cohort 3: Early Integration of Encorafenib–Cetuximab Plus FOLFIRI Improves Response in BRAF V600E mCRC

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients

Gut Onc Lab: The Leading Voices in GI Cancers

Latest Podcasts

Latest Videos

Latest Updates from OncoNexus

Latest Updates in Genitourinary Oncology

Latest Updates in Breast Cancer

Latest Updates in Lung Cancer

Latest Updates in GI Cancer

Latest Updates in Oncology